Refining Targeted Therapy Opportunities for BRAF-Mutant Melanoma

被引：5
|
作者：
Jenkins, Russell W. [1 ,2 ]
Barbie, David A. [1 ]
机构：
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[2] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Div Med Oncol, Boston, MA USA
来源：
CANCER DISCOVERY | 2017年 / 7卷 / 08期
关键词：
RESISTANCE; INHIBITORS; MITF; NRAS;
D O I：
10.1158/2159-8290.CD-17-0607
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Identifying molecular and cellular features associated with resistance to targeted BRAF/MAPK pathway inhibition may guide development of novel therapeutic approaches. Integrated, comparative analysis of genomic and functional data in sensitive and resistant cell lines unveils novel targetable regulators of resistance to MAPK pathway inhibition in melanoma.
引用
收藏
页码：799 / 801
页数：3
相关论文
共 50 条
  • [31] BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma
    Queirolo, Paola
    Spagnolo, Francesco
    CANCER AND METASTASIS REVIEWS, 2017, 36 (01) : 35 - 42
  • [32] Novel mechanisms of resistance in BRAF-mutant melanoma
    Poulikakos, Poulikos I.
    CLINICAL CANCER RESEARCH, 2012, 18 (10)
  • [33] BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma
    Paola Queirolo
    Francesco Spagnolo
    Cancer and Metastasis Reviews, 2017, 36 : 35 - 42
  • [34] Braf-Mutant Melanomas: Biology and Therapy
    Pelosi, Elvira
    Castelli, Germana
    Testa, Ugo
    CURRENT ONCOLOGY, 2024, 31 (12) : 7711 - 7737
  • [35] Our clinical experience with targeted tumor treatment in patients with BRAF-mutant metastatic melanoma
    Ocsai, H.
    Baltas, E.
    Varga, A.
    Kemeny, L.
    Olah, J.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 : 74 - 74
  • [36] BRAF-Targeted Therapy in the Treatment of BRAF-Mutant High-Grade Gliomas in Adults
    Johanns, Tanner M.
    Ansstas, George
    Dahiya, Sonika
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (04): : 451 - 454
  • [37] Melanoma Targeted Therapies beyond BRAF-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches
    Khaddour, Karam
    Maahs, Lucas
    Avila-Rodriguez, Ana Maria
    Maamar, Yazan
    Samaan, Sami
    Ansstas, George
    CANCERS, 2021, 13 (22)
  • [38] ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma
    Ojha, Rani
    Leli, Nektaria M.
    Onorati, Angelique
    Piao, Shengfu
    Verginadis, Ioannis I.
    Tameire, Feven
    Rebecca, Vito W.
    Chude, Cynthia I.
    Murugan, Sengottuvelan
    Fennelly, Colin
    Noguera-Ortega, Estela
    Liu, Shujing
    Xu, Xiaowei
    Krepler, Clemens
    Xiao, Min
    Xu, Wei
    Wei, Zhi
    Frederick, Dennie T.
    Boland, Genevieve
    Mitchell, Tara C.
    Karakousis, Giorgos C.
    Schuchter, Lynn M.
    Flaherty, Keith T.
    Zhang, Gao
    Herlyn, Meenhard
    Koumenis, Constantinos
    Amaravadi, Ravi K.
    CANCER DISCOVERY, 2019, 9 (03) : 396 - 415
  • [39] Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma
    Ziogas, Dimitrios C.
    Konstantinou, Frosso
    Bouros, Spyros
    Gogas, Helen
    EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (01) : 53 - 62
  • [40] Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma
    Aya, F.
    Fernandez-Martinez, A.
    Gaba, L.
    Victoria, I.
    Tosca, M.
    Pineda, E.
    Gascon, P.
    Prat, A.
    Arance, A.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (01): : 119 - 124
12345